Latest NovoCure Stories
Based on the results of the trial's pre-specified interim analysis all control patients in the EF-14 phase III trial will be offered the opportunity to cross over to receive Tumor Treating Fields
Planned interim analysis demonstrates the EF-14 Phase III trial met its endpoints of progression-free survival and overall survival ST. HELIER, Jersey, Dec.
Data presented today as a late-breaking abstract at the Society for Neuro-Oncology 2014 Annual Meeting in Miami demonstrated the EF-14 trial met its primary endpoint of progression-free survival and
Analyses of PRiDe, a registry of 457 recurrent glioblastoma patients, show that patients treated with the NovoTTF(TM)-100A System at their first and second recurrences had median overall survivals
#TuneIn2GBM Social Media Campaign to Raise Awareness to Help Fight a Deadly Form of Brain Cancer PORTSMOUTH, N.H., May 8, 2014 /PRNewswire/ -- For the second consecutive year, Novocure
Novocure today announced that the U.S. Food and Drug Administration (FDA) approved the NovoTTF-100A System (NovoTTF) for the treatment of adult patients with glioblastoma multiforme (GBM) brain tumors, following tumor recurrence after receiving chemotherapy.
WASHINGTON, March 17, 2011 /PRNewswire/ -- Novocure announced today that the U.S.
- The word or words serving to define another word or expression, as in a dictionary entry.